Anti-GIP Antibody Picoband® Fluoro550 Conjugated

Gastric inhibitory polypeptide (GIP), also known as the glucose-dependent insulinotropic peptide, is an inhibiting hormone of the secretin family of hormones. GIP is thought to have significant effects on fatty acid metabolism through stimulation of lipoprotein lipase activity in adipocytes. Additionally, GIP release has been demonstrated in the ruminant animal and may play a role in nutrient partitioning in milk production (lipid metabolism) . Recently, GIP appeared as a major player in bone remodelling. It was evidenced that genetic ablation of the GIP receptor in mice resulted in profound alterations of bone microarchitecture through modification of the adipokine network. Furthermore, the deficiency in GIP receptors has also been associated in mice with a dramatic decrease in bone quality and a subsequent increase in fracture risk.

E. coli-derived human GIP recombinant protein (Position: Y52-Q93) . Human GIP shares 92.9% and 95.2% amino acid (aa) sequence identity with mouse and rat GIP, respectively.

1. Gaudin-Audrain C, Irwin N, Mansur S, Flatt PR, Thorens B, Baslé M, Chappard D, Mabilleau G (Mar 2013) . Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice. Bone 53 (1) : 221–30. 2. Mieczkowska A, Irwin N, Flatt PR, Chappard D, Mabilleau G (Oct 2013) . Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality.Bone 56 (2) : 337–42.